273 related articles for article (PubMed ID: 27904868)
1. Predictive Ability of
Kiyoto S; Sugawara Y; Hosokawa K; Nishimura R; Yamashita N; Ohsumi S; Mochizuki T
Asia Ocean J Nucl Med Biol; 2016; 4(1):3-11. PubMed ID: 27904868
[TBL] [Abstract][Full Text] [Related]
2. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
3. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304
[TBL] [Abstract][Full Text] [Related]
4. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
5. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
[TBL] [Abstract][Full Text] [Related]
7. The Value of
Tatar G; Özkul Ö; Alçin G
Mol Imaging Radionucl Ther; 2022 Jun; 31(2):123-129. PubMed ID: 35770978
[TBL] [Abstract][Full Text] [Related]
8. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of Dmax and %ΔSUVmax of
Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
[TBL] [Abstract][Full Text] [Related]
10. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Charon-Barra C; Berriolo-Riedinger A; Desmoulins I; Lorgis V; Kanoun S; Coutant C; Fumoleau P; Cochet A; Brunotte F
Clin Cancer Res; 2015 Dec; 21(24):5460-8. PubMed ID: 26130460
[TBL] [Abstract][Full Text] [Related]
11. The role of basal metabolic and volumetric
Kepenek F; Karaoğlan H; Can C; Kömek H; Kaplan İ; Etem H; Ebinç S; Kavak Ş; Gündoğan C
Hell J Nucl Med; 2022; 25(3):235-246. PubMed ID: 36507879
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA;
J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256
[TBL] [Abstract][Full Text] [Related]
14. MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer.
Aiba T; Uehara K; Nihashi T; Tsuzuki T; Yatsuya H; Yoshioka Y; Kato K; Nagino M
Ann Surg Oncol; 2014 Jun; 21(6):1801-8. PubMed ID: 24531702
[TBL] [Abstract][Full Text] [Related]
15. The Value of Semiquantitative Parameters Derived from
Urso L; Evangelista L; Alongi P; Quartuccio N; Cittanti C; Rambaldi I; Ortolan N; Borgia F; Nieri A; Uccelli L; Schirone A; Panareo S; Arnone G; Bartolomei M
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497351
[TBL] [Abstract][Full Text] [Related]
16. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E
Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075
[TBL] [Abstract][Full Text] [Related]
17. Textural features of
Cheng L; Zhang J; Wang Y; Xu X; Zhang Y; Zhang Y; Liu G; Cheng J
Ann Nucl Med; 2017 Aug; 31(7):544-552. PubMed ID: 28646331
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
19. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
20. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Seban RD; Arnaud E; Loirat D; Cabel L; Cottu P; Djerroudi L; Hescot S; Loap P; Bonneau C; Bidard FC; Huchet V; Jehanno N; Berenbaum A; Champion L; Buvat I
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4024-4035. PubMed ID: 37606858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]